Yep, the Oscars are over, but it doesn't mean we're done talking about it! You can relive the best of the night! Check out what celebs, readers (and you!) had to say about the musical numbers, speeches – and a certain reigning Sexiest Man Alive! – on Twitter last night.
WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.
The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.
Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.
"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."
Cobleigh helped conduct the key studies of the drug at the Chicago facility.
The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.
The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.
Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.
FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.
Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.
FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer
Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.
Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.
Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.
Samsung (005930) is finally gaining some momentum in the tablet market after a slow start with the original Galaxy Tab, which launched in late 2010. The South Korean consumer electronics giant now has a number of slates available in the 7- and 10-inch ranges, but Apple’s (AAPL) 8-inch iPad mini opened new doors for mid-size tablets following its release this past November. Samsung was already putting a mid-range tablet together when the iPad mini debuted last year, and now the company is finally ready to take the wraps off its latest Note series device: The Galaxy Note 8.0.
[More from BGR: BlackBerry 10 browser smokes iOS 6 and Windows Phone 8 in comparison test [video]]
With a footprint that measures 8.3 inches by 5.4 inches, the Galaxy Note 8.0 can be used comfortably with one hand but provides much more screen real estate than a 7-inch tablet. As this slate falls into Samsung’s Note lineup, it also includes an S Pen stylus and an updated suite of stylus-ready apps.
[More from BGR: The end of unlimited BBM could erode BlackBerry’s standing in emerging markets]
Samsung’s new 8-inch Note slides perfectly into the gap between the Galaxy Note II and the Galaxy Note 10.1. “It’s the best of both worlds,” Samsung Mobile’s director of product planning Shoneel Kolhatkar said during a briefing.
Key specs include an 8-inch 1280 x 800-pixel TFT display, a 1.6GHz quad-core processor, 2GB of RAM, 32GB or 64GB of internal storage, microSDXC support, a 4,600 mAh battery, Android 4.1.2 Jelly Bean and a sleek case that is 25% thinner that the Galaxy Note 10.1. The Note 8.0 also includes an integrated 3G antenna, but a Wi-Fi-only version will be available shortly after the 3G version launches.
While Samsung focused mainly on the consumer market with the first Galaxy Note tablet, The Note 8.0 is as much about enterprise as it is about consumers. ”The next big thing is being extended to business,” Samsung Electronics’ marketing boss Travis Merrill told reporters at a recent meeting in New York City. Great features like the ability to run multiple apps at once in different windows extends the slate’s utility in a business environment, and Samsung’s “SAFE” certification means the tablet is secure.
Other intriguing features include a new “Readers Mode,” which conserves battery, dims the screen and changes the tablet’s contrast settings to make it a great eReader, and a host of new second screen features that make the Note 8.0 a solid TV companion.
The Galaxy Note 8.0 will launch in a number of markets around the world including the United States beginning in the second quarter this year. Pricing has not yet been announced.
Samsung’s full press release follows below, and be sure to check out our hands-on impressions of Samsung’s new Galaxy Note 8.0 tablet.
INTRODUCING THE GALAXY NOTE 8.0,
A NEW ERA OF PORTABILITY AND EVERYDAY PRODUCTIVITYSEOUL, Korea [February 24, 2011] – Samsung Electronics Co., Ltd, a global leader in digital media and digital convergence technologies, today announced the launch of the 8 inch tablet, the GALAXY Note 8.0; a new era of intelligent Note technology set to re-ignite the mid-size tablet category that Samsung established in 2010. Providing unrivalled multimedia performance within a compact one-hand-grip screen, the GALAXY Note 8.0 has the power and advanced technology to evolve the tablet experience and ensure you achieve new levels of efficient multi-tasking while benefitting from superb voice call functionality*. Furthermore, the intelligent S Pen brings together the latest innovation and the ease of using a traditional pen and paper; creating a sophisticated mobile experience that will enhance life on the go.
“Back in 2010 the launch of the first Samsung GALAXY Tab with 7 inch screen opened a new chapter in the mobile industry. Now almost three years later, Samsung continues to evolve the sector that meets the demands of modern life.” said JK Shin, President of the IT & Mobile Communications Division at Samsung Electronics.
“The GALAXY Note 8.0 breaths fresh life into the category as it delivers the perfect fusion of portability and everyday productivity – the result is a pioneering, pocket-sized solution that enhances and enriches our everyday lives, whether at work or play,” added Shin.
At the core of the GALAXY Note 8.0’s innovative solutions are beneficial functions, including multi-window options to split the portable 8inch screen and allow optimal access to a number of live applications; a new generation of Samsung’s intelligent S Pen with advanced usability; access to a suite of S Note templates and tools that allow you to create, edit, manage and share everyday documents; the Samsung “reading mode” technology to enjoy e books with optimized resolution, video and voice calls*. In addition, a suite of exciting new content and services are pre-loaded for users at no additional cost including, for the very first time on Samsung GALAXY tablet, the innovative Flipboard, and Awesome Note.
A smart diary for life on the go
Slim and compact enough to become the perfect on-the-go work and play companion, the GALAXY Note 8.0 brings powerful performance and functionality to support even the most demanding of lifestyles. Designed to store and manage your personal and professional data efficiently, the new era device gives users the perfect pocket-sized hands-on organizational tool. Practical S Note templates and S Planner feature help to manage everyday tasks, including meeting notes, to-do lists and even personal diary entries. All content can be entered and updated with the finest of detail thanks to the evolution of the intelligent Samsung S Pen. Enhanced precision is offered with Handwriting-to-Text conversion and advanced Productivity Tools that support formula and shape recognition are now available at the touch of your S Pen.
New content and services
GALAXY Note 8.0 is packed with pre-loaded content and apps specifically for the value maximizing, mass multimedia consumer. Upgraded Chat-On provides easy instant messaging and group chatting in multiple formats – images, video, voice, contacts – for simple, enjoyable communication. Awesome Note, an integrated application that is introduced in android tablet for the first time with NOTE 8.0, is capable of unlimited note-taking uses including Memo, Diary and Must-remember lists. With Flipboard, your news, social network and other feeds come together in one stylish, flippable format so you can enjoy all your news and life’s great moments in one place. Flipboard developed a customized version of its application exclusively for Samsung that allows users to take the S Pen’s hover feature and preview article headers beneath Flipboard’s main screen tiles. Finally, Smart Remote, gives you a universal remote control and electronic programming guide allowing you to manage TV and video watching seamlessly.
A new age of S Pen intelligence
Optimized to aid personalized creativity, the Samsung S Pen has evolved to increase everyday usability and enhance creation expression. Embedded within the tablet, the S Pen is an extension of the GALAXY Note 8.0. Removing the S Pen from the device will automatically launch innovative features such as Pen Detection that will suggest adapted menus that it thinks you’ll need and Page Buddy, a feature that will intuitively activate your most recently adapted S Note home screen.
S Pen technology is now so advanced that it doesn’t even have to touch the screen. With Air View, the S Pen needs only to hover over the screen to see previews of videos, emails, photos and appointments on SPlanner without opening the file or application in full. S Pen Gesture allows images and content to be easily edited and cropped, whilst Paper Artist and Photo Note allow photos to be artistically personalized.
In addition, for the very first time in GALAXY NOTE category, you can use S Pen to control the physical menu/back buttons on the device with WACOM technology.
Maximizing mass multimedia consumption
Creative multi-tasking with the GALAXY Note 8.0 is effortless due to innovative Dual View feature, two multi window options that seamlessly allow you to facilitate multi-screen usage. Dual View’s split screen accommodates optimal operation of different apps, such as launching the S Note on the web browser screen and allowing content to be resized, dragged and dropped as required.
Multi-tasking is extended to phone calls*. Pop Up Note allows you to access S Note at any time to keep track of key actions and Pop Up Video ensures you can keep surfing the web whilst chatting – content windows can be easily resized by pinching to enlarge or reduce.
Perfect info-tainment partner
Packed with features to engage, entertain and excite, the GALAXY Note 8.0 supports your practical everyday needs. Reading Mode transforms the GALAXY Note 8.0 into an e-Book reader, provides the optimal reading conditions to ensure you can curl up and enjoy a good book. You can even turn it into a universal remote control with Smart Remote, to seamlessly manage TVs, set-up boxes, DVD & Blu-ray players.
This article was originally published on BGR.com
Gadgets News Headlines – Yahoo! News
02/22/2013 at 05:00 PM ET
Mom Kourtney Kardashian has one! Aunts Kim and Khloé own one too. And now Penelope Disick is the latest family member to add Balenciaga‘s chic city tote to her closet.
“Penelope is wearing the little Balenciaga bag that I got her for Christmas!” Kim posted on Instagram Friday, along with an adorable photo of the mom-to-be with her 7½-month-old niece and her mini yellow handbag.
Is Kim gearing up for her little one? If she has a little girl, we have no doubt her wardrobe will be the envy of the playground. Although the expectant reality star recently revealed that if it’s up to dad-to-be Kanye West, their baby will be wearing lots of “big chains and leather pants.”
And to be fair, Penelope wasn’t the only Kardashian-Jenner kid to receive luxe fashions for Christmas. Kylie and Kendall also scored during the holidays.
Courtesy Kim Kardashian; Inset: Rex USA
– Shanelle Rein-Olowokere
WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.
The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.
Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.
"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."
Cobleigh helped conduct the key studies of the drug at the Chicago facility.
The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.
The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.
Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.
FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.
Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.
FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer
Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.
Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.
Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.
NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.
Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.
Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.
"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.
Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.
But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.
National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.
"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.
OPTIONS BULLS TARGET GAINS
The spending cuts, if they go ahead, could hit the defense industry particularly hard.
Yet in the options market, bulls were targeting gains in Lockheed Martin Corp
Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.
"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.
The stock ended up 0.6 percent at $88.12 on Friday.
If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp
General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.
EYES ON GDP DATA, APPLE
The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.
U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.
Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.
Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.
On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.
(Additional reporting by Doris Frankel; Editing by Kenneth Barry)
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
NYSE
American International Group Inc., up $ 1.17 at $ 38.45
The insurer posted a $ 4 billion loss at the end of 2012 on costs from Sandy, but its operating profit topped Wall Street expectations.
Hewlett-Packard Co., up $ 2.10 at $ 19.20
The latest quarter showed some progress at the PC maker, which has been struggling with a shift toward smartphones and tablets.
Abercrombie & Fitch Co., down $ 2.19 at $ 46.86
The teen clothing retailer’s profit rose during the holiday quarter, but sales trends deteriorated. It plans to close up to 50 U.S. stores.
Rackspace Hosting Inc., down 74 cents at $ 54.59
The website hosting company is cutting prices for its cloud bandwidth by one-third and setting tiered prices for other services.
Nasdaq
Zynga Inc., up 23 cents at $ 3.19
The online games maker could be closer to offering lucrative gambling games in the U.S. after a Nevada law legalized online gambling.
Aruba Networks Inc., up $ 4.60 at $ 25.40
The maker of equipment for wireless networks reverted to a profit and posted higher revenue in its latest quarter as demand grew.
WebMD Health Corp., up $ 4.14 at $ 20.44
The health website predicted another sales decline for this year, but the drop was not as steep as Wall Street expected.
Charter Communications Inc., up $ 7.99 at $ 85.02
New customers and more video and advertising sales helped the cable TV provider narrow its fourth-quarter loss.
Gaming News Headlines – Yahoo! News
02/22/2013 at 01:00 PM ET
Denise Truscello/Wireimage
Mario Lopez is a man of his word.
Following a December wedding, the EXTRA host declared he and wife Courtney would get to work expanding their family immediately — and he wasn’t kidding.
In January, the couple discovered they were indeed expecting.
“Mario and I are so excited to add to our family! I found out a month ago and surprised Mario with the good news at breakfast,” Courtney tells PEOPLE.
But the proud parents aren’t the only ones gearing up for a new addition. Big sister Gia Francesca, 2, already has babies on the brain.
“Gia kind of understands that there is a baby in my belly,” Courtney notes. “She also told me our dog Julio has a baby in his belly — so who knows!”
Despite a bumpy start — “I had a rough couple of weeks when I first found out,” she shares — the mom-to-be is feeling better and already sporting quite the blossoming belly. “I am showing so much faster this time around,” she says.
And with warmer weather on the way, Courtney will be swathing her bump in floor-length frocks — but plans on forgoing a few fashion ensembles from her past.
“I love being pregnant in the summer! I live in maxi dresses,” she says. “Looking back at my first pregnancy, there are certain things that I wore and I have no idea why. I looked horrible and I won’t do that again!”
Originally from Pittsburgh, the expectant mama is thrilled to have settled down with her growing family on the West Coast. Her only wish? That her children will one day enjoy a winter wonderland.
“I don’t miss the East Coast at all — especially the humidity,” she explains. “The one thing I do want my children to experience from an early age is snow. There is nothing like being a kid playing in the snow.”
– Anya Leon
LONDON (Reuters) - Stock index futures pointed to a higher open on Wall Street on Friday, rebounding after the S&P 500 <.spx> posted its worst two-day loss since November.
Futures for the S&P 500, the Dow Jones and the Nasdaq 100 were up 0.2-0.3 percent at 0958 GMT.
European shares rose and German Bund futures fell on Friday after a better-than-expected German Ifo survey.
Shares in Hewlett-Packard
Chipmaker Texas Instruments Inc
Fellow chipmaker Marvell Technology Group Ltd
Insurer American International Group Inc reported fourth-quarter results that beat Wall Street expectations, helping its shares rise 4.2 percent in after hours trade.
Citigroup Inc
Newmont Mining Corp
Private equity firm KKR & Co LP
Interpublic Group, the second-biggest U.S. advertising and marketing group, is expected to follow larger rival Omnicom in reporting upbeat quarterly results, with earnings per shares seen up $0.03 year on year to $0.53 on higher revenue from the United States.
The Dow Jones industrial average <.dji> fell 46.92 points, or 0.34 percent, to 13,880.62 on Thursday. The Standard & Poor's 500 Index <.spx> lost 9.53 points, or 0.63 percent, to 1,502.42. The Nasdaq Composite Index <.ixic> dropped 32.92 points, or 1.04 percent, to close at 3,131.49.
(Reporting By Francesco Canepa/editing by Chris Pizzey, London MPG Desk, +44 (0)207 542-4441)
CAIRO (Reuters) - The opposition Syrian National Coalition is willing to negotiate a peace deal to end the country's civil war but President Bashar al-Assad must step down and cannot be a party to any settlement, members agreed after debating a controversial initiative by their president.
The meeting of the 70-member Western, Arab and Turkish-backed coalition began on Thursday before Syrian Foreign Minister Walid al-Moualem is due for talks in Moscow, one of Assad's last foreign allies, and as U.N. mediator Lakhdar Brahimi renews efforts for a deal.
After an angry late night session in which coalition president Moaz Alkhatib came under strong criticism from Islamist and liberal members alike for proposing talks with Assad's government without setting what they described as clear goals, the coalition adopted a political document that demands Assad's removal and trial for the bloodshed, members said.
A draft document seen by Reuters that was circulated for debate said Assad cannot be party to any political solution and has to be tried, but did not directly call for his removal.
"We have adopted the political document that sets the parameters for any talks. The main addition to the draft is a clause about the necessity of Assad stepping step down," said Abdelbasset Sida, a member of the coalition's 12 member politburo who has criticized Alkhatib for acting alone.
"We removed a clause about a need for Russian and U.S. involvement in any talks and added that the coalition's leadership has to be consulted before launching any future initiatives," he added.
Still, the agreement marked a softening of tone by the coalition because previously it had insisted that Assad must step down before any talks with his government could begin.
In an indication that Syria's strongman remains defiant, Brahimi said Assad had told him he will remain president until his term ends in 2014 and then run for re-election.
Brahimi told al-Arabiya television he wants to see a transitional government formed in Syria that would not answer to any higher authority and lasts until U.N.-supervised elections take place in the country.
"I am of the view that U.N. peacekeepers should come to Syria as happened in other countries," Brahimi said.
BOMB, AIR STRIKES
The opposition front convened in Cairo on a day when a car bomb jolted central Damascus, killing 53 people, wounding 200 and incinerating cars on a busy highway close to the Russian Embassy and offices of the ruling Baath Party.
Syrian state television blamed the suicide blast on "terrorists". Central Damascus has been relatively insulated from the 23-month conflict that has killed around 70,000 people, but the bloodshed has shattered suburbs around the capital.
In the southern city of Deraa near the border with Jordan, activists said warplanes bombed the old quarter for the first time since March 2011, when the town set in a wheat-growing plain rose up against Assad, starting a national revolt.
A rebel officer in the Tawheed al-Janoub brigade which led an offensive this week in Deraa said there were at least five air strikes on Thursday. The Syrian Observatory for Human Rights said 18 people were killed, including eight rebel fighters.
Coalition member Munther Makhos, who was forced into exile in the 1970s for his opposition to Assad's father, the late President Hafez al-Assad, said supplies from Iran and Russia were giving government forces an awesome firepower advantage.
"It would be surreal to imagine that a political solution is possible. Bashar al-Assad will not send his deputy to negotiate his removal. But we are keeping the door open," Makhos said.
Makhos is the only Alawite in the Islamist-dominated coalition. The Alawite sect, an offshoot of Shi'ite Islam which accounts for about 10 percent of Syria's population but makes up most of the intelligence apparatus and dominates the army and the political system, has generally remained behind Assad.
With Alawites feeling increasingly threatened by a violent Sunni backlash, Alkhatib, a cleric from Damascus who played a role in the peaceful protest movement against Assad at the beginning of the uprising in 2011, has been calling on Alawites to join the revolution, saying their participation will help preserve the social fabric of the country.
Alkhatib's supporters say the initiative has popular support inside Syria from people who want to see a peaceful departure of Assad and a halt to the war that has increasingly pitted his fellow Alawites against Syria's Sunni Muslim majority.
But rebel fighters on the ground, over whom Alkhatib has little control, are generally against the proposal.
The Syrian Islamic Liberation Front, which represents armed brigades, said in a statement it was opposed to Alkhatib's initiative because it ignored the revolt's goal of "the downfall of the regime and all its symbols".
"We are demanding his accountability for the bloodshed and destruction he has wreaked. I think the message is clear enough," said veteran opposition campaigner Walid al-Bunni, who supports Alkhatib.
Alkhatib formulated the initiative in broad terms last month after talks with the Russian and Iranian foreign ministers in Munich but without consulting the coalition, catching the umbrella organization by surprise.
Among Alkhatib's critics is the Muslim Brotherhood, the only organized group in the political opposition.
A Brotherhood source said the group will not scuttle the proposal because it was confident Assad is not interested in a negotiated exit, which could help convince the international community to support the armed struggle for his removal.
"Russia is key," the source said, speaking on condition of anonymity. "We are showing the international community that we are willing to take criticism from the street but the problem is Assad and his inner circle. They do not want to leave."
PLAY FOR RUSSIA
Russia hopes Alkhatib will visit soon in search of a breakthrough. Bunni said Alkhatib would not go to Moscow without the coalition's approval and that he would not be there at the same time as Moualem.
"In my opinion Alkhatib should not go to Moscow until Russia stops sending arms shipments to the Assad regime," Bunni said.
Formal backing by the coalition for Alkhatib's initiative gives it more weight internationally and undermines Assad supporters' argument that the opposition is too divided to be considered a serious player, opposition sources said.
Coalition members and diplomats based in the region said Brahimi asked Alkhatib in Cairo last week to seek full coalition backing for his plan, which resembles the U.N. envoy's own ideas for a negotiated settlement.
One diplomat in contact with the opposition and the United Nations had said a coalition approval of Alkhatib's initiative could help change the position of Russia, which has blocked several United Nations Security Council resolutions on Syria.
The diplomat said only a U.N. resolution could force Assad to the negotiating table, and a U.N. "stabilization force" may still be needed to prevent an all-out slide into a civil war.
"Brahimi has little hope that Assad will agree to any serious talks," the diplomat said. "Differences are narrowing between the United States and Russia about Syria but Moscow remains the main obstacle for Security Council action."
(Editing by Paul Taylor and Mohammad Zargham)
Copyright © News consolidation. All rights reserved.
Design 
And Business Directories
